My laboratory research explores alternative pre-mRNA splicing in prostate cancer (PCa) biology, and liquid biopsy-derived molecular biomarkers of treatment outcomes. My clinical research investigates chemo-preventative strategies to reduce low risk PCa progression, and surgical alternatives to cytotoxic chemotherapy for metastatic testicular cancer.
Androgen Receptor Burden and Poor Response to Abiraterone or Enzalutamide in TP53 Wild-Type Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol (2019) 5(7):1060-1062. PMID: 31046065
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis. Genome Medicine (2018) 10(1):85. PMID: 30458854
Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up. Eur Urol Focus (2018) 4(3):351-359. PMID: 28753802
Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study. J Clin Oncol (2017) 35(31):3566-3574. PMID: 28930493
Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol (2014) 66(1):32-9. PMID: 24054872
2020-2021- CRUK Barts Centre Development Fund, Exploiting PTEN loss in Hypoxic Tumour Cells (Principal Investigator), £10,000
2018-2021- QMUL Life Sciences Initiative PhD Studentship, Understanding alternative splicing in human cancer by proteomics informed by transcriptomics (PIT) (Co-applicant with Professor Conrad Bessant), ~£80,000
2017-2021- The Urology Foundation/The John Black Charitable Foundation Project Grant, Androgen receptor splice variants in prostate cancer (Principal Investigator), £249,999
My laboratory-based research programme explores a link between alternative pre-mRNA splicing (AS), a ubiquitous post-transcriptional gene regulatory mechanism, and prostate cancer (PCa) phenotypes. During AS, coding (exons) and non-coding (introns) regions of a gene are shuffled to create protein isoforms with different functions. AS is regulated by trans-acting RNA-binding proteins (RBPs), and tightly coupled to transcription. We are studying the link between dysregulation of transcriptional and intracellular signalling processes and AS, mediated by RBPs.
Our translational research examines how blood-derived liquid biopsy molecular biomarkers can be used to improve treatment outcomes for PCa patients. With NHS colleagues, we are investigating minimally-invasive surgical alternatives to chemotherapy for metastatic testicular cancer to reduce the therapy burden and toxicity. In collaboration with the Wolfson Institute of Preventative Medicine, we are exploring how minimally-toxic chemo-preventative strategies may reduce PCa progression on active surveillance.
The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing Guo T, Wang Y, Jia J et al. Frontiers in Cell and Developmental Biology (2021) 8(7)
Peri-operative, functional and early oncologic outcomes of salvage robotic-assisted radical prostatectomy after high-intensity focused ultrasound partial ablation Thompson JE, Sridhar AN, Shaw G et al. BMC Urology (2020) 20(7)
Identification of altered biological processes in heterogeneous RNA-sequencing data by discretization of expression profiles Lauria A, Peirone S, Giudice MD et al. Nucleic Acids Research (2020) 48(7) 1730-1747
Early outcomes of robot-assisted radical prostatectomy following completion of a structured training curriculum: a single surgeon cohort study Sehmbi AS, Sridhar AN, Sahadevan K et al. Journal of Clinical Urology (2020) (7)
Reply by Authors Xu L, Mao X, Grey A et al. The Journal of urology (2020) 203(1) 81-82
106PElevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer De Laere B, Crippa A, Ghysel C et al. Annals of Oncology (2019) 30(10) v30-v31
Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer De Laere B, Crippa A, Ghysel C et al. ANNALS OF ONCOLOGY (2019) 30(11)
Noninvasive Detection of Clinically Significant Prostate Cancer Using Circulating Tumor Cells. Xu L, Mao X, Grey A et al. The Journal of Urology 203(1) 101097JU000000000000-101097JU000000000000
Abstract 2580: Investigation of plasma exosomal miRNA as a biomarker and its potential function in prostate cancer castration resistant development Guo T, Wang Y, Mao X et al. (2019) (10) 2580-2580
Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound. Thompson JE, Sridhar AN, Tan WS et al. J Urol (2019) 201(1) 1134-1143